Clinical trials: Gastric (Stomach) Cancer
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Advanced Cancer, Various, NOS
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma
To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-833923 administered alone, in combination with lenalidomide plus dexamethasone, or in combination with bortezomib in subjects with relapsed or…
- Trial name
- NCT00884546
- Testing
- BMS-833923, Lenalidomide, Dexamethasone
- Where
- 8 sites in United States
- Volunteers
- 27 people
- Sponsor
- Bristol-Myers Squibb
Gastric Cancer
Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer
To explore the efficacy and safety of Fruquintinib combined with Sintilimab and XELOX in the first-line treatment of unresectable advanced metastatic gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT06094868
- Testing
- Fruquintinib
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Laparoscopic, Gastrectomy
Reduced Port Laparoscopic Gastrectomy for Gastric Cancer
Reduced port laparoscopic gastrectomy has been adopted in clinical. The safety and outcome of reduced port laparoscopic gastrectomy has not been systematically evaluated.
- Trial name
- NCT04295473
- Testing
- Reduced port laparoscopic gastrectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Nanchong Central Hospital
Gastric Cancer
Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Trial name
- NCT00002783
- Testing
- cisplatin, floxuridine, fluorouracil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer
Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
This cohort study is divided into two parts: Part A: Registry Cohort All patients with non-metastatic, MMRd/MSI-H colorectal cancers (and other gastrointestinal cancers for exploratory analysis) who have signed the general…
- Conditions
- Quality of Life (QOL), Mismatch Repair Deficient Colorectal Cancer, Microsatellite Instability-High Colorectal Cancer, Stage II Colorectal Cancer
- Trial name
- RESIST (NCT07829081)
- Testing
- Active surveillance after complete response to immunotherapy in MMRd GI cancers, Stand of Care
- Where
- 3 sites in Switzerland
- Volunteers
- 234 people
- Sponsor
- University Hospital, Basel, Switzerland
Stomach Cancer
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together.
- Trial name
- NCT05427383
- Testing
- KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Shanghai JMT-Bio Inc.
Stomach Neoplasms, Paclitaxel
Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis
IPXELOX will investigate the safety, tolerability, and antitumor activity of intraperitoneal paclitaxel in combination with chemotherapy in patients with advanced gastric cancer with peritoneal metastasis.
- Conditions
- Stomach Neoplasms, Paclitaxel, Peritoneal Metastases
- Trial name
- IPXELOX (NCT04943653)
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Seoul St. Mary's Hospital
Gastric Cancer
Effect of Gastric Cancer Specialist Training Program in Laparoscopic Gastric Cancer Surgery（STP-LRG-1）
To prospectively evaluate the effect of the gastric cancer specialist training program of Fujian Medical University Union Hospital on laparoscopic gastric cancer surgery.
- Trial name
- NCT05585437
- Testing
- gastric cancer specialist training program
- Where
- China
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University
Gastric Adenocarcinoma, Cancer Metastatic
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study
Peritoneal metastasis is a common pattern in advanced gastric cancer leading to a terminal condition in a very short time. Whatever recent progress regarding systemic chemotherapy using multi drugs association median survival is…
- Conditions
- Gastric Adenocarcinoma, Cancer Metastatic, Chemotherapy Effect
- Trial name
- PIPAC EstoK 01 (NCT04065139)
- Testing
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC), Standard chemotherapy
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Gastric Cancer Stage IV
Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
The single arm clinical study is to evaluate the efficacy and safety of an anti-PD-1 antibody (Toripalimab) combined with chemotherapy (docetaxel or nab-Paclitaxel) in patients with advanced gastric cancer who failed first-line…
- Trial name
- NCT04563975
- Testing
- Toripalimab, Docetaxel, nab-paclitaxel
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Tao Zhang
Gastric Cancer
Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis
A single-center, observational study, integrated biomarker analysis of HIPEC combined Programmed cell death 1 /Programmed cell death 1 ligand 1(PD1/PDL1)inhibitor in previously treated patients of advanced gastric cancer with…
- Trial name
- NCT05661110
- Testing
- Observational
- Volunteers
- 46 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Solid Tumor, Soft Tissue Sarcoma
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CAR (NCT03960060)
- Testing
- CCT301-59
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Advanced Solid Tumor, Metastatic Solid Tumor
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
- Trial name
- NCT06974110
- Testing
- MOMA-341, Irinotecan, Immunotherapy
- Where
- 15 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- MOMA Therapeutics
Gastric Cancer
A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer
An open-label, dose escalation and maximum tolerated dose (MTD) and/or recommended phase II dose (RPTD) study of fruquintinib combined with paclitaxel in patients with advanced gastric cancer who did not respond to first-line…
- Trial name
- NCT02415023
- Testing
- fruquintinib+paclitaxel
- Where
- 3 sites in China
- Volunteers
- 34 people
- Sponsor
- Hutchison Medipharma Limited
Esophagitis
Risk of Cancer Among Pantoprazole Users
The primary objective is to assess whether the risk of gastric cancer is increased in pantoprazole users compared to users of other proton pump inhibitors.
- Trial name
- NCT01322633
- Testing
- Does not apply
- Volunteers
- 61,864 people
- Sponsor
- Pfizer
Immunotherapy, Gastric Cancer (GC)
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
- Conditions
- Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy
- Trial name
- NCT07165847
- Testing
- Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Gastric Cancer
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer
This is a prospective pilot study to evaluate the safety and feasibility of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and gastroesophageal junction.
- Trial name
- NCT05396326
- Testing
- Oxaliplatin, Teysuno, Transarterial arterial chemoinfusion and embolism (TACiE)
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.